RBC Lowers Eyepoint Pharmaceuticals Target Price to $5.00

Investment analysts at Royal Bank Of Canada (RBC) maintained their 'sector perform' rating for Eyepoint Pharmaceuticals (NASDAQ:EYPT), with a target price of $5.00, down from $37.00 previously.

This follows the company's release of topline data from its LUGANO trial, which showed DURAVYU was non-inferior to on-label aflibercept in an ad hoc analysis excluding nine patients with asymmetric vision loss unrelated to wet AMD.

RBC's target price points to a potential upside of 2.67% from the stock's previous close of $4.87, which is also Eyepoint Pharmaceuticals' current market capitalization of $419.84 million and its P/E ratio of -1.30.